• Local progression-free interval every 12 weeks for 2 years after randomization and then every 24 weeks for 3 years [ Designated as safety issue: No ]
  

• Acute toxicity at 4 weeks after randomization [ Designated as safety issue: Yes ]
  
• Late toxicity at 12 weeks after randomization [ Designated as safety issue: Yes ]
  
• Tumor response at 12 weeks after randomization [ Designated as safety issue: No ]
  
• Overall survival every 12 weeks for 2 years after randomization and then every 24 weeks for 3 years [ Designated as safety issue: No ]
  
• Health economic assessment every 12 weeks for 2 years after randomization and then every 24 weeks for 3 years [ Designated as safety issue: No ]
  

OBJECTIVES:

Primary

• Compare the local progression-free interval in patients with follicular non-Hodgkin's lymphoma (NHL) treated with 2 different regimens of low-dose radiotherapy.

Secondary

• Compare acute toxicity at 4 weeks in patients treated with these regimens.
• Compare late toxicity in patients treated with these regimens.
• Compare tumor response at 12 weeks in patients treated with these regimens.
• Compare overall survival in patients treated with these regimens.
• Assess the health economics of these regimens in these patients.

OUTLINE: This is a multicenter, randomized study. Patients are randomized to one of two treatment arms.

• Arm I : Patients undergo low-dose radiotherapy once daily on days 1 and 2.
• Arm II : Patients undergo low-dose radiotherapy once daily on days 1-5, 8-12, 15, and 16.

In both arms, treatment continues in the absence of disease progression or unacceptable toxicity.

After completion of study therapy, patients are followed periodically for 5 years and then annually thereafter.

Peer Reviewed and Funded or Endorsed by Cancer Research UK

PROJECTED ACCRUAL: A total of 650 patients will be accrued for this study.